Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study

Zhou, Wenbin; Ding, Qiang; Pan, Hong; Wu, Naping; Liang, Mengdi; Huang, Yaoyu; Chen, Lin; Zha, Xiaoming; Li, Xiaoan; Wang, Shui

doi:10.1186/1471-2407-14-662

Cited by 17 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(43) A family history of lung cancer was associated with increased risk of hormone receptor positive breast cancer in a case-control study in China. (44) No previous study has reported an association of family history of cervical cancer with increased risk of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women

Bethea

Rosenberg

Castro‐Webb

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Evidence on the relation of family history of cancers other than breast cancer to breast cancer risk is conflicting and most studies have not assessed specific breast cancer subtypes. Methods We assessed the relation of first degree family history of breast, prostate, lung, colorectal, ovarian, cervical cancer, and lymphoma or leukemia, to risk of estrogen receptor positive (ER+), ER−, and triple negative breast cancer in data from the African American Breast Cancer Epidemiology and Risk Consortium. Multivariable logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results There were 3,023 ER+ and 1,497 ER− breast cancer cases (including 696 triple negative cases) and 17,420 controls. First degree family history of breast cancer was associated with increased risk of each subtype: OR=1.76 (95% CI 1.57–1.97) for ER+, 1.67 (1.42–1.95) for ER−, and 1.72 (1.38–2.13) for triple negative breast cancer. Family history of cervical cancer was associated with increased risk of ER− (OR=2.39, 95% CI 1.36–4.20), but not ER+ cancer. Family history of both breast and prostate cancer was associated with increased risk of ER+ (3.40, 2.42–4.79) and ER− (2.09, 1.21–3.63) cancer, but family history of both breast and lung cancer was associated only with ER− cancer (2.11, 1.29–3.46). Conclusions A family history of cancers other than breast may influence risk of breast cancer and associations may differ by subtype. Impact Greater surveillance and counseling for additional screening may be warranted for women with a family history of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women

Bethea

Rosenberg

Castro‐Webb

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Previous studies have indicated that a family history of other types of cancer, such as colon cancer, prostate cancer, and ovarian cancer, is associated with an increased risk of breast cancer occurrence (6–8). However, studies on the presence of germline mutations in patients with breast cancer with a family history of tumors are limited, to the best of our knowledge.…”

Section: Introductionmentioning

confidence: 99%

A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors

Jiang

Wang

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

Previous studies have demonstrated that a family history of breast cancer is considered a risk factor, and hereditary factors may be involved in breast cancer pathogenesis. Next-generation sequencing techniques were used to analyze 111 cancer-associated genes in patients with breast cancer with a familial history of malignant tumors in the pre-experiment and a novel variant, receptor tyrosine-protein kinase erbB-2 ( ERBB2 ) c.338G>A: p.R113Q was identified in two cases of breast cancer. ERBB2 is considered an important oncogene, and overexpression or mutation of the ERBB2 gene may lead to the occurrence or metastasis of tumors. To assess a potential association between rs185670819 and breast cancer, 117 patients with breast cancer and a familial history of any cancer, who were diagnosed by experienced pathologists at the Xijing Hospital (Shaanxi, China) between July 2015 and December 2016, were recruited. The presence of the missense variant was confirmed using bi-directional Sanger sequencing of samples from the patients with breast cancer and 250 healthy controls. The effects of the missense mutation on the structure and function of ERBB2 were analyzed in silico . The missense variant, R113Q, in patients with breast cancer with a familial history of malignant tumors in China, was present in 8 patients [6.8% (95% CI: 3.21–13.45)] and 3 of 250 healthy controls [1.2% (95% CI: 0.31–3.76; OR=6.04, 95% CI: 1.573–23.214, P=0.009)]. Of the 8 patients with the R113Q variant, 6 patients had a family history of cancer of the digestive system. The present study suggests that ERBB2 c.338G>A: p.R113Q may be a potential risk factor in the development and progression of breast cancer.

show abstract

“…Lung squamous cell carcinoma is one of the most common subtypes of lung cancer, remaining large cancer-related death in China ( Peng et al, 2015 ). It is reported that lung cancer may be caused by many factors, including environment (smoky coal, radon) ( Kim et al, 2014 ; Torres-Duran et al, 2015 ), life style (smoking, diets) ( Gnagnarella et al, 2013 ; Yang, 2011 ), human papillomavirus ( Hsu et al, 2013 ), chronic pulmonary infection (it can be caused by S. aureus ) ( Mulanovich, Mulanovich & Rolston, 2008 ; Parker & Prince, 2012 ), genetic factors (family history) ( Zhou et al, 2014 ) and so on, which may be the risk factors of LUSC. The development of individualized accurate diagnosis and therapy have been faced with huge challenges due to immense difference in multiple parameters such as molecular, pathology, surgery, and radiology among LUSC patients ( Pavel & Vasile, 2016 ).…”

Section: Discussionmentioning

confidence: 99%

Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas

Yang

Sui

Liang

2017

PeerJ

View full text Add to dashboard Cite

BackgroundLung cancer is considered as one of the most frequent and deadly cancers with high mortality all around the world. It is critical to find new biomarkers for early diagnosis of lung cancer, especially lung squamous cell carcinoma (LUSC). The Cancer Genome Atlas (TCGA) is a database which provides both cancer and clinical information. This study is a comprehensive analysis of a novel diagnostic biomarker for LUSC, based on TCGA.Methods and ResultsThe present study investigated LUSC-specific key microRNAs (miRNAs) from large-scale samples in TCGA. According to exclusion criteria and inclusion criteria, the expression profiles of miRNAs with related clinical information of 332 LUSC patients were obtained. Most aberrantly expressed miRNAs were identified between tumor and normal samples. Forty-two LUSC-specific intersection miRNAs (fold change >2, p < 0.05) were obtained by an integrative computational method, among them six miRNAs were found to be aberrantly expressed concerning characteristics of patients (gender, lymphatic metastasis, patient outcome assessment) through Student t-test. Five miRNAs correlated with overall survival (log-rank p < 0.05) were obtained through the univariate Cox proportional hazards regression model and Mantel–Haenszel test. Then, five miRNAs were randomly selected to validate the expression in 47 LUSC patient tissues using quantitative real-time polymerase chain reaction. The results showed that the test findings were consistent with the TCGA findings. Also, the diagnostic value of the specific key miRNAs was determined by areas under receiver operating characteristic curves. Finally, 577 interaction mRNAs as the targets of 42 LUSC-specific intersection miRNAs were selected for further bioinformatics analysis.ConclusionThis study indicates that this novel microRNA expression signature may be a useful biomarker of the diagnosis for LUSC patients, based on bioinformatics analysis.

show abstract

Risk of breast cancer and family history of other cancers in first-degree relatives in Chinese women: a case control study

Cited by 17 publications

References 41 publications

Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women

Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women

A germline alteration of ERBB2 increases the risk of breast cancer in Chinese Han women with a familial history of malignant tumors

Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas

Contact Info

Product

Resources

About